4.4 Article

American College of Rheumatology White Paper on Performance Outcome Measures in Rheumatology

期刊

ARTHRITIS CARE & RESEARCH
卷 68, 期 10, 页码 1390-1401

出版社

WILEY-BLACKWELL
DOI: 10.1002/acr.22936

关键词

-

资金

  1. Centers for Medicare & Medicaid Services, an agency of the US Department of Health and Human Services [HHSM-500-2013-13018I Task Order HHSM-500-T0001]
  2. VA Connecticut Healthcare System
  3. NIH
  4. National Institute of Arthritis and Musculoskeletal and Skin Diseases
  5. Archstone Foundation
  6. Robert L. Kroc Chair in Rheumatic and Connective Tissue Diseases
  7. Agency for Healthcare Research and Quality [R01-HS024412]
  8. Russell/Engleman Medical Research Center for Arthritis
  9. Horizon
  10. GlaxoSmithKline
  11. Zimmer
  12. University of North Carolina
  13. pfizer
  14. Genentech

向作者/读者索取更多资源

Objective. To highlight the opportunities and challenges of developing and implementing performance outcome measures in rheumatology for accountability purposes. Methods. We constructed a hypothetical performance outcome measure to demonstrate the benefits and challenges of designing quality measures that assess patient outcomes. We defined the data source, measure cohort, reporting period, period at risk, measure outcome, outcome attribution, risk adjustment, reliability and validity, and reporting approach. We discussed outcome measure challenges specific to rheumatology and to fields where patients have predominantly chronic, complex, ambulatory care-sensitive conditions. Results. Our hypothetical outcome measure was a measure of rheumatoid arthritis disease activity intended for evaluating Accountable Care Organization performance. We summarized the components, benefits, challenges, and tradeoffs between feasibility and usability. We highlighted how different measure applications, such as for rapid cycle quality improvement efforts versus pay for performance programs, require different approaches to measure development and testing. We provided a summary table of key take-home points for clinicians and policymakers. Conclusion. Performance outcome measures are coming to rheumatology, and the most effective and meaningful measures can only be created through the close collaboration of patients, providers, measure developers, and policymakers. This study provides an overview of key issues and is intended to stimulate a productive dialogue between patients, practitioners, insurers, and government agencies regarding optimal performance outcome measure development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据